Search

Your search keyword '"O’Connor, Christopher M."' showing total 258 results

Search Constraints

Start Over You searched for: Author "O’Connor, Christopher M." Remove constraint Author: "O’Connor, Christopher M." Database Complementary Index Remove constraint Database: Complementary Index
258 results on '"O’Connor, Christopher M."'

Search Results

2. Use of win time for ordered composite endpoints in clinical trials.

4. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.

5. Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS‐986231).

10. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.

11. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.

12. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.

14. Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial.

15. The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial.

17. Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).

18. Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure.

20. Myocarditis Temporally Associated With COVID-19 Vaccination.

21. Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy.

22. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial.

23. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial.

24. Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial.

28. Depression and heart failure: the lonely comorbidity.

29. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.

30. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo‐controlled trial.

32. A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF).

33. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.

34. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.

35. Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions.

36. Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.

37. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.

39. Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction.

40. Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry.

41. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.

43. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.

44. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

45. Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?

46. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

47. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.

48. Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.

Catalog

Books, media, physical & digital resources